Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Lenalidomide + Tafasitamab-cxix|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Lenalidomide||Revlimid||IMiD-1||Revlimid (lenalidomide) is a thalidomide analog which regulates cytokine production and stimulates T cells and NK cells activity (PMID: 24328678). Revlimid (lenalidomide) is FDA approved for use in multiple myeloma, relapsed or refractory Mantle cell lymphoma, and in combination with a rituximab product in follicular lymphoma and marginal zone lymphoma (FDA.gov).|
|Tafasitamab-cxix||Monjuvi||MOR00208|XmAb5574|MOR-208|MOR208||CD19 Antibody 10||Monjuvi (tafasitamab-cxix) is an CD19-targeted antibody with an engineered Fc region, which may result in an increased antibody-dependent cell-mediated cytotoxicity response against CD19-expressing tumor cells (PMID: 23277329, PMID: 32511983). Monjuvi (tafasitamab-cxix) is FDA approved for use in combination with Revlimid (lenalidomide) in patients with relapsed or refractory diffuse large B cell lymphoma (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||diffuse large B-cell lymphoma||not applicable||Lenalidomide + Tafasitamab-cxix||FDA approved||Actionable||In a Phase II trial (L-MIND) that supported FDA approval, the combination of Revlimid (lenalidomide) and Monjuvi (tafasitamab-cxix) was well tolerated in patients with previously treated diffuse large B-cell lymphoma and resulted in an objective response rate of 60% (48/80, 34 complete responses, 14 partial responses) and stable disease in 14% (11/80) of patients, with a median progression-free survival of 12.1 months (PMID: 32511983; NCT02399085).||32511983 detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02399085||Phase II||Lenalidomide + Tafasitamab-cxix||A Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL||Active, not recruiting|
|NCT02005289||Phase II||Lenalidomide + Tafasitamab-cxix Ibrutinib + Tafasitamab-cxix||Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL||Active, not recruiting|